Today: 7 February 2026
Subscribe
Browse Category

Pharmaceuticals News 21 November 2025 - 25 November 2025

SRPT Stock Today, November 25, 2025: Sarepta Rises on SRP‑1003 Progress While Elevidys Risks Still Loom

SRPT Stock Today, November 25, 2025: Sarepta Rises on SRP‑1003 Progress While Elevidys Risks Still Loom

Shares of Sarepta Therapeutics (NASDAQ: SRPT) head into Tuesday’s session trying to build on a rare rally, as investors digest a positive safety update for its experimental RNA therapy SRP‑1003 and weigh it against fresh FDA warnings and trial setbacks tied to its gene therapy Elevidys. SRPT stock today at a glance As of Monday’s close (November 24, 2025), here’s where SRPT stands: In other words, Monday’s bounce was meaningful, but comes after a brutal collapse from triple‑digit levels earlier in 2025. New SRP‑1003 data: a rare bright spot for SRPT stock On Monday, Sarepta released a progress update for
25 November 2025
··
VKTX Stock Today, November 25, 2025: Can Viking Therapeutics Keep Riding the Obesity Drug Wave?

VKTX Stock Today, November 25, 2025: Can Viking Therapeutics Keep Riding the Obesity Drug Wave?

Viking Therapeutics (NASDAQ: VKTX) heads into the Tuesday, November 25, 2025 session trading in the mid‑$30s, still digesting last week’s major milestone: the company has finished enrolling patients in its pivotal Phase 3 obesity trial VANQUISH‑1 ahead of schedule and above its original target. Viking Therapeutics InvestorRoom As of yesterday’s close (Monday, November 24), VKTX changed hands at $34.65, implying a market capitalization of roughly $3.9 billion. Stock Titan Shares sit well below their 52‑week high of $56.25, but far above the 52‑week low of $18.92, underscoring how volatile the weight‑loss drug trade has become. Investing.com+1 With Phase 3 trials
25 November 2025
··
MRK Stock Today: Merck Jumps on Wells Fargo Upgrade and Keytruda Momentum (November 24, 2025)

MRK Stock Today: Merck Jumps on Wells Fargo Upgrade and Keytruda Momentum (November 24, 2025)

Merck & Co., Inc. (NYSE: MRK) is in rally mode on Monday, November 24, 2025. By early afternoon, MRK stock is trading around $101–$102 per share, up roughly 3.5–3.8% on the day, near its highest levels of 2025 and within a few percent of its 52‑week high. StockAnalysis The move comes as Wells Fargo upgraded Merck to “Overweight” from “Equal Weight” and lifted its price target to $125, alongside fresh FDA approvals and pipeline updates that strengthen the company’s story beyond flagship cancer drug Keytruda. Merck.com MRK stock today: price action and key stats As of early afternoon trading on
24 November 2025
·
BMY Stock Soars on Factor XIa Catalyst and Hematology Investor Event (Nov. 24, 2025)

BMY Stock Soars on Factor XIa Catalyst and Hematology Investor Event (Nov. 24, 2025)

Published: November 24, 2025Ticker: Bristol Myers Squibb Company (NYSE: BMY) Key takeaways This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. BMY stock today: a 4% move that stands out Bristol Myers Squibb shares climbed sharply on Monday, with BMY changing hands around $48.24, up roughly $1.99 from Friday’s close near $46.25—a gain of about 4.3% on the day. Intraday, the stock traded between roughly $46.39 and $48.63, on volume in the low‑ to mid‑teens of millions of shares—broadly in line with recent average daily trading activity,
24 November 2025
Eli Lilly Hits $1 Trillion: Weight‑Loss Drugs Turn a 150‑Year‑Old Pharma Into a Tech‑Sized Giant

Eli Lilly Hits $1 Trillion: Weight‑Loss Drugs Turn a 150‑Year‑Old Pharma Into a Tech‑Sized Giant

Published November 24, 2025 Eli Lilly has done something no other health‑care company has ever achieved: it has joined the $1 trillion market‑capitalization club, a group previously dominated almost entirely by technology giants like Apple, Microsoft and Nvidia. After briefly crossing the 13‑figure threshold on Friday, Lilly’s stock was still trading around $1,058 per share on Monday, valuing the Indianapolis‑based drugmaker at roughly $1.0 trillion and cementing its status as the first pharmaceutical company in that elite group. Reuters+1 The catalyst is clear: a once‑in‑a‑generation boom in highly effective weight‑loss and diabetes drugs such as Mounjaro and Zepbound, built on
24 November 2025
··
Novo Nordisk Stock Plunges After Alzheimer’s Drug Failure: NVO Price, News and Outlook Today (24 November 2025)

Novo Nordisk Stock Plunges After Alzheimer’s Drug Failure: NVO Price, News and Outlook Today (24 November 2025)

Danish pharma giant Novo Nordisk is under intense pressure today after its high‑profile Alzheimer’s trials for semaglutide failed, sending the stock to multi‑year lows and capping a brutal year for NVO shareholders. Novo Nordisk stock today: how far has NVO fallen? Novo Nordisk’s Alzheimer’s setback is hitting the share price hard on Monday, 24 November 2025: Despite the sell‑off, Novo Nordisk still carries a market capitalisation in the $210–215 billion range, according to multiple data providers — down sharply from its 2024 peak, but still firmly in “mega‑cap” territory. Companies Market Cap+2MacroTrends+2 For investors, today’s move is less about short‑term
24 November 2025
·
Recursion Pharmaceuticals (RXRX) Stock Today: ‘Hold’ Rating, New Institutional Buying and AI Drug Discovery Hype — November 23, 2025

Recursion Pharmaceuticals (RXRX) Stock Today: ‘Hold’ Rating, New Institutional Buying and AI Drug Discovery Hype — November 23, 2025

Snapshot: Where RXRX Stands Going Into the New Week Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) closed Friday, November 21, 2025, at $4.17, up 8.31% on the day after bouncing off the low‑$3 range earlier in the week. Volume was heavy at roughly 33 million shares, and the stock now trades near the bottom of its 52‑week range of $3.79–$12.36.StockInvest+1 The company’s market capitalization sits a little above $2.1 billion, and technically RXRX remains below both its 50‑day and 200‑day moving averages (around $5.2 and $5.1 respectively), underscoring how deep the recent pullback has been despite Friday’s sharp bounce.MarketBeat Because U.S. markets
24 November 2025
···
Tonix Pharmaceuticals Stock on November 23, 2025: Tonmya Launch, Bigger Buyback, and a $400M ATM Shape the TNXP Trade

Tonix Pharmaceuticals Stock on November 23, 2025: Tonmya Launch, Bigger Buyback, and a $400M ATM Shape the TNXP Trade

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) heads into Sunday, November 23, 2025, with its first commercial fibromyalgia drug now on pharmacy shelves, a beefed‑up share repurchase program, and a sharply expanded at‑the‑market (ATM) equity facility. Together, those moves are redefining the risk‑reward profile of this small‑cap biotech just as investors focus on how quickly new product Tonmya can ramp. Tonix Pharmaceuticals Holding Corp.+2Investing.com+2 TNXP stock today: price, performance and valuation U.S. markets are closed today, but the latest full trading session for Tonix Pharmaceuticals stock (TNXP) was Friday, November 21, 2025: On the fundamentals side, MarketBeat data paint a classic
23 November 2025
··
Pfizer (PFE) on 23 Nov 2025: Metsera Deal, Cancer Win and a 7% Dividend

Pfizer (PFE) on 23 Nov 2025: Metsera Deal, Cancer Win and a 7% Dividend

Published: November 23, 2025 Pfizer Inc. (NYSE: PFE) heads into the new week with its share price stuck around the mid‑$20s, a near‑7% dividend yield, and a flurry of fresh headlines that could shape the stock’s next move. Over the past few days the pharma giant has closed a multibillion‑dollar obesity acquisition, secured a major new U.S. cancer approval, sold $6 billion in new bonds and agreed to a $41.5 million legal settlement in Texas – while new analysis published today highlights both its long‑term potential and its risks. Reuters+3Pfizer+3Pfizer+3 Below is a roundup of the latest news and analysis
23 November 2025
··
Pfizer Stock Today, November 22, 2025: 7% Dividend, $6 Billion Bond Sale and New Health Scare Put PFE Back in Focus

Pfizer Stock Today, November 22, 2025: 7% Dividend, $6 Billion Bond Sale and New Health Scare Put PFE Back in Focus

Pfizer stock heads into the weekend trading just above $25, with investors digesting a busy week of news: a strong Q3 earnings beat, a fresh FDA cancer-drug approval, completion of a multi‑billion‑dollar obesity deal, a new $6 billion bond issue – and even a headline‑grabbing bird flu case that once again reminds markets of Pfizer’s role in vaccines and antivirals. Benzinga+3Business Wire+3Pfizer+3 Pfizer stock price today: where PFE stands on November 22, 2025 U.S. markets are closed today (Saturday), so the latest full trading session for Pfizer Inc. (NYSE: PFE) is Friday, November 21, 2025: Data providers like IndMoney and
23 November 2025
···
Merck (MRK) Stock Today: Mini‑Tender Warning, Dividend Hike and Drug Wins – 22 November 2025

Merck (MRK) Stock Today: Mini‑Tender Warning, Dividend Hike and Drug Wins – 22 November 2025

Merck & Co., Inc. (NYSE: MRK) is firmly in the spotlight this weekend as the U.S. pharma giant juggles shareholder protection, a higher dividend, and fresh regulatory wins — all while its share price trades near the upper end of its 12‑month range. Note: This article refers to Merck & Co., Inc., the U.S. company based in Rahway, New Jersey (ticker MRK on the NYSE), not German Merck KGaA (Xetra: MRK). Key takeaways for 22 November 2025 Merck (MRK) stock snapshot As of the latest trading data, Merck shares are trading around $97.76, up about 2.9% on the day, after
22 November 2025
··
Novo Nordisk Stock on 21 November 2025: NVO Slips as Denmark Grants Eye-Damage Payouts and GLP‑1 Price War Escalates

Novo Nordisk Stock on 21 November 2025: NVO Slips as Denmark Grants Eye-Damage Payouts and GLP‑1 Price War Escalates

Novo Nordisk stock is back in the spotlight today, 21 November 2025, as a cluster of breaking headlines hits the world’s most closely watched weight‑loss drug maker. As of late morning in New York, Novo Nordisk’s U.S. ADR (NYSE: NVO) is trading around $47.07, down roughly 1.1% on the day, giving the company a market value close to $213 billion. In Copenhagen, Novo Nordisk’s B‑shares finished the session around DKK 305, down nearly 3% and extending a steep slide that has left the stock down about 45% year‑to‑date. Investing.com+1 Today’s trading comes against a flurry of fresh news: Below is
21 November 2025
···
1 … 44 45 46 47 48 … 56

Stock Market Today

Alphabet stock drops for a fourth straight day as AI spending jitters linger

Alphabet stock drops for a fourth straight day as AI spending jitters linger

7 February 2026
Alphabet shares fell 2.53% to $322.86 Friday, marking a fourth straight decline as investors questioned heavy AI-related spending. The Nasdaq slipped Thursday after Alphabet detailed up to $185 billion in capex, while the Dow and S&P 500 rose Friday on chipmaker gains. U.S. markets reopen Monday, with attention on Alphabet’s outlook and upcoming jobs and inflation data.
BBAI stock jumps 16% into BigBear.ai share-vote week — what to watch next

BBAI stock jumps 16% into BigBear.ai share-vote week — what to watch next

7 February 2026
BigBear.ai Holdings shares surged 15.7% Friday to $4.72 ahead of a key shareholder vote on doubling authorized shares to 1 billion. Options trading was heavy, with a put/call ratio of 0.19. The company recently announced deals in AI customs technology and a partnership with Abu Dhabi’s AD Ports Group. The special meeting is set for Feb. 18, with online voting open until late Feb. 17.
American Airlines stock jumps nearly 8% as airlines rally — what to watch next week

American Airlines stock jumps nearly 8% as airlines rally — what to watch next week

7 February 2026
American Airlines shares jumped 7.6% to $15.24 Friday, rebounding with a broad rally that sent the Dow past 50,000 for the first time. Investors are watching the carrier’s battle with United at Chicago O’Hare, where a summer capacity surge could trigger a fare war. American also announced new Philadelphia–Porto service for 2027 and launched a centennial inflight menu.
Go toTop